Skip to main content
Springer Nature Link
Log in

Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents

  • Review Article
  • Published:
Save article
View saved research
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Adolescent smoking remains a public health problem. Despite concerns regarding adolescent nicotine dependence, few well-designed smoking cessation studies have been conducted with teen smokers. This is particularly true regarding pharmacologic treatments for nicotine dependence. Currently, pharmacologic aids are not recommended for treating adolescent nicotine dependence, as efficacy has not been shown in this population.

This review includes studies that have examined the efficacy of pharmacotherapy for smoking abstinence and/or reduction in cigarette consumption among adolescent smokers who want to quit smoking, laboratory-based adolescent studies that have examined the efficacy of these medications in reducing cravings and/or withdrawal symptoms, and/or studies that have assessed the tolerability of medications for smoking cessation in adolescent smokers. It provides information on the pharmacologic action of each medication, the efficacy of each medication for adolescent smoking cessation, the tolerability of each medication based on reported adverse events, and compliance with the medication protocols.

Thirteen relevant articles were identified and included in the review. Nicotine patch (NP), nicotine gum, nicotine nasal spray, bupropion, and varenicline have been studied in adolescent smokers. The adverse events reported in the studies on pharmacology for adolescent smoking suggest that the side effect profiles for nicotine replacement therapy, bupropion, and varenicline are similar to those reported in adult studies. There is some evidence of efficacy of NP and bupropion at the end of treatment (efficacy of varenicline has not been assessed), but none of the medications included in this review were efficacious in promoting long-term smoking cessation among adolescent smokers. It is noted that many of the study protocols did not follow the recommended dose or length of pharmacotherapy for adults, rendering it difficult to determine the true efficacy of medication for adolescent smoking cessation. Future efficacy studies are warranted before recommending pharmacotherapy for adolescent smoking cessation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from €39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

References

  1. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Healthy People 2020: proposed HP2020 objectives [online]. Available from URL: http://www.healthypeople.gov/hp2020 [Accessed 2011 Feb 1]

  2. Substance Abuse and Mental Health Service Administration, Office of Applied Studies. The NSDUH report. Trends in substance use, dependence or abuse, and treatment among adolescents: 2002–2007. Rockville (MD): Substance Abuse and Mental Health Service Administration, 2008 Dec 4

    Google Scholar 

  3. Johnston LD, O’Malley PM, Bachman JG, et al. Monitoring the Future national results on adolescent drug use: overview of key findings, 2009. NIH publication no. 10-7583. Bethesda (MD): National Institute on Drug Abuse, 2010

    Google Scholar 

  4. Department of Health and Human Services. Preventing tobacco use among young people: a report of the Surgeon General (DHHS publication no. CDC 89-8411). Washington, DC: U.S. Government Printing Office, 1994

    Google Scholar 

  5. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville (MD): U.S. Department of Health and Human Services, 2008 May

    Google Scholar 

  6. Bailey SR, Harrison CT, Jeffery CJ, et al. Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence? Addict Behav 2009; 34(12): 1017–22

    Article  PubMed  Google Scholar 

  7. Killen JD, Ammerman S, Rojas N, et al. Do adolescent smokers experience withdrawal effects when deprived of nicotine? Exp Clin Psychopharmacol 2001; 9(2): 176–82

    Article  PubMed  CAS  Google Scholar 

  8. Colby SM, Tiffany ST, Shiffman S, et al. Are adolescent smokers dependent on nicotine? A review of the evidence. Drug Alcohol Depend 2000; 59Suppl. 1: S83–95

    Article  PubMed  Google Scholar 

  9. Rojas NL, Killen JD, Haydel KF, et al. Nicotine dependence among adolescent smokers. Arch Pediatr Adolesc Med 1998; 152(2): 151–6

    Article  PubMed  CAS  Google Scholar 

  10. Hanson K, Zylla E, Allen S, et al. Cigarette reduction: an intervention for adolescent smokers. Drug Alcohol Depend 2008; 95(1-2): 164–8

    Article  PubMed  Google Scholar 

  11. Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994; 271(24): 1940–7

    Article  PubMed  CAS  Google Scholar 

  12. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD000146

    Google Scholar 

  13. Hudmon KS, Corelli RL, Prokhorov AV. Current approaches to pharma-cotherapy for smoking cessation. Ther Adv Respir Dis 2010; 4(1): 35–47

    Article  PubMed  Google Scholar 

  14. Smith TA, House Jr RF, Croghan IT, et al. Nicotine patch therapy in adolescent smokers. Pediatrics 1996; 98(4): 659–67

    PubMed  CAS  Google Scholar 

  15. Hurt RD, Croghan GA, Beede SD, et al. Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatr Adolesc Med 2000; 154(1): 31–7

    PubMed  CAS  Google Scholar 

  16. Hanson K, Allen S, Jensen S, et al. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res 2003; 5(4): 515–26

    PubMed  Google Scholar 

  17. Roddy E, Romilly N, Challenger A, et al. Use of nicotine replacement therapy in socioeconomically deprived young smokers: a community-based pilot randomised controlled trial. Tob Control 2006; 15: 373–6

    Article  PubMed  Google Scholar 

  18. Moolchan ET, Robinson ML, Ernst M, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics 2005; 115(4): e407–14

    Article  PubMed  Google Scholar 

  19. Rubinstein ML, Benowitz NL, Auerback GM, et al. A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics 2008; 122(3): e595–600

    Article  PubMed  Google Scholar 

  20. Upadhyaya HP, Brady KT, Wang W. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study. J Am Acad Child Adolesc Psychiatry 2004; 43(2): 199–205

    Article  PubMed  Google Scholar 

  21. Niederhofer H, Huber M. Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results. Pharmacotherapy 2004; 24(11): 1524–8

    Article  PubMed  CAS  Google Scholar 

  22. Killen JD, Robinson TN, Ammerman S, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 2004; 72(4): 729–35

    Article  PubMed  Google Scholar 

  23. Muramoto ML, Leischow SJ, Sherrill D, et al. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med 2007; 161(11): 1068–74

    Article  PubMed  Google Scholar 

  24. Gray KM, Carpenter MJ, Baker NL, et al. Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abuse Treat 2011; 40(1): 77–86

    Article  PubMed  Google Scholar 

  25. CHANTIX® (varenicline) tablets: US prescribing information. New York: Pfizer Labs, 2010

  26. Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010; 8(8): 1–15

    Google Scholar 

  27. Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2009; 31(1): 177–89

    Article  PubMed  CAS  Google Scholar 

  28. Slotkin TA. Nicotine and the adolescent brain: insights from an animal model. Neurotoxicol Teratol 2002; 24(3): 369–84

    Article  PubMed  CAS  Google Scholar 

  29. Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies, dare we recommend nicotine replacement therapy in pregnant women and adolescents? Neurotoxicol Teratol 2008; 30(1): 1–19

    Article  PubMed  CAS  Google Scholar 

  30. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295(1): 321–7

    PubMed  CAS  Google Scholar 

  31. ZYBAN® (bupropion hydrochloride) sustained-released tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2010

  32. Ossip-Klein DJ, Bigelow G, Curry S, et al. Task force 1: classification and assessment of smoking behavior. Health Psychol 1986; 5 Suppl.: 3–11

    Article  PubMed  Google Scholar 

  33. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; (1): CD000031

    Google Scholar 

  34. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337(17): 1195–202

    Article  PubMed  CAS  Google Scholar 

  35. Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003; 163(19): 2337–44

    Article  PubMed  CAS  Google Scholar 

  36. Wagner KD. Pharmacotherapy for major depression in children and adolescents. Prog in Neuropsychopharmacol Biol Psychiatry 2005; 29(5): 819–26

    Article  CAS  Google Scholar 

  37. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52(3): 985–94

    Article  PubMed  CAS  Google Scholar 

  38. Sussman S, Sun P, Dent CW. A meta-analysis of teen cigarette smoking cessation. Health Psychol 2006; 25(5): 549–57

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Preparation of this paper was supported, in part, by the National Cancer Institute Grant # R01 CA 118035. We thank Sean P. David, MD, for his comments and review of the paper. All authors declare they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Family Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mailcode FM, Portland, OR, 97239, USA

    Steffani R. Bailey

  2. Stanford Prevention Research Center, Stanford University School of Medicine, Palo Alto, CA, USA

    Erin E. Crew, Emily C. Riske & Joel D. Killen

  3. Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA

    Seth Ammerman & Thomas N. Robinson

Authors
  1. Steffani R. Bailey
    View author publications

    Search author on:PubMed Google Scholar

  2. Erin E. Crew
    View author publications

    Search author on:PubMed Google Scholar

  3. Emily C. Riske
    View author publications

    Search author on:PubMed Google Scholar

  4. Seth Ammerman
    View author publications

    Search author on:PubMed Google Scholar

  5. Thomas N. Robinson
    View author publications

    Search author on:PubMed Google Scholar

  6. Joel D. Killen
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Steffani R. Bailey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bailey, S.R., Crew, E.E., Riske, E.C. et al. Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents. Pediatr Drugs 14, 91–108 (2012). https://doi.org/10.2165/11594370-000000000-00000

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.2165/11594370-000000000-00000

Keywords

Profiles

  1. Steffani R. Bailey View author profile